Anti-Rheumatic Drugs - Niger | Statista Market Forecast

The projected revenue in the Anti-Rheumatic Drugs market in Niger is expected to reach US$2.70m by the year 2024.
It is anticipated that the revenue will display an annual growth rate (CAGR 2024-2029) of 2.00%, leading to a market volume of US$2.99m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with US$34.70bn in the year 2024.
Niger's demand for anti-rheumatic drugs is driven by the high prevalence of rheumatoid arthritis among its population.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Niger has been increasing steadily over the past few years.

Customer preferences: Niger has a high prevalence of rheumatoid arthritis, which is the primary driver of the demand for anti-rheumatic drugs in the country. The majority of the customers prefer generic drugs due to their lower cost as compared to branded drugs.

Trends in the market: The Anti-Rheumatic Drugs market in Niger has been witnessing a shift towards biologic drugs due to their higher efficacy and targeted action. However, the high cost of these drugs remains a significant barrier to their adoption, and the market for biologics remains limited. The market for traditional disease-modifying anti-rheumatic drugs (DMARDs) continues to dominate the market due to their affordability and availability.

Local special circumstances: Niger is a low-income country with limited healthcare resources, which has led to challenges in the access and availability of anti-rheumatic drugs. The country has a weak healthcare infrastructure, and there is a shortage of trained healthcare professionals. This situation has led to a limited availability of specialized care for rheumatoid arthritis patients.

Underlying macroeconomic factors: The economy of Niger is heavily dependent on agriculture, which accounts for over 90% of its exports. The country has a low GDP per capita, and the majority of the population lives below the poverty line. The healthcare sector in Niger is severely underfunded, with limited resources allocated towards research and development of new drugs. The government has limited resources to subsidize the cost of drugs, which has led to a limited availability of affordable drugs for the population. The COVID-19 pandemic has further strained the healthcare system in Niger, diverting resources from other areas, including the treatment of rheumatoid arthritis. In conclusion, the Anti-Rheumatic Drugs market in Niger is primarily driven by the high prevalence of rheumatoid arthritis in the country. The market is dominated by traditional DMARDs due to their affordability and availability, although there is a shift towards biologics due to their higher efficacy. The limited availability of healthcare resources and weak infrastructure are significant challenges to the market's growth. The government's limited resources and the COVID-19 pandemic have further compounded these challenges.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.